Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04844-ySource: DataRank Database

A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors is a research paper published in Cancer Chemotherapy and Pharmacology (2025). On theSindex it has a DataRank of 0.104. It has been cited 1 time.

N/A

0.104DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.41)OA: hybridTopics (46)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.104

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (22)

Shivaani Kummar ORCID,Larry Rubinstein ORCID,Jennifer Zlott,Geraldine O’Sullivan Coyne ORCID,Vincent Chung ORCID

Live enrichment

PubMed:41428220 OpenAlex:https://openalex.org/W7116671514

NCI NIH HHS

Grant: UM1 CA186690

NCI NIH HHS

Grant: UM1 CA186717

NCI NIH HHS

Grant: U24 CA247643

NCI NIH HHS

Grant: U24 CA247648

NCI NIH HHS

Grant: R50 CA211241

NCI NIH HHS

Grant: P30 CA047904

FWCI

0.41

Citation Percentile

0.7%

Citation Trend

2026

hybridLicense: cc-by

journalhttps://link.springer.com/content/pdf/10.1007/s00280-025-04844-y.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00280-025-04844-y.pdf

publisherhttps://link.springer.com/article/10.1007/s00280-025-04844-y

journalhttps://doi.org/10.1007/s00280-025-04844-y

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41428220

Fields of Study

Epigenetics and DNA MethylationChemical Reactions and IsotopesCancer Research and TreatmentsHumansMaleMiddle AgedFemaleNeoplasmsAgedTetrahydrouridineAdultAdministration, OralAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineDose-Response Relationship, DrugDNA (Cytosine-5-)-Methyltransferase 1DNA MethylationMaximum Tolerated Dose

MeSH Terms

DNA (Cytosine-5-)-Methyltransferase 1Administration, OralAdultAgedAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedNeoplasmsTetrahydrouridineDNA MethylationMaximum Tolerated Dose

Keywords

Refractory (planetary science)RegimenPhases of clinical researchDiseaseTumor suppressor genePharmacokineticsMaximum tolerated doseProgressive diseaseCancer epigeneticsCirculating tumor cellsDNMT1 inhibitorsEpigenetic modifying agentsP16

Sustainable Development Goals

SDG 0: Good health and well-being